Clinical studies in 23 centers in the Asian giant validated the effectiveness of the monoclonal antibody Nimotuzumab.
The anticancer drug used to treat pancreatic and nasopharyngeal carcinoma, Nimotuzumab, received approval for the expansion of its use in China, one of the nations with the highest incidence of cancer on the planet.
The registration of the monoclonal antibody, approved by the National Drug Administration of the Asian giant, is considered a milestone in biotechnological cooperation between both countries, which occurs after clinical studies were carried out in 23 centers in that nation, which validated the effectiveness of the drug. against pancreatic cancer.
The medicine, developed from research by the Chinese-Cuban joint company Biotech Pharma (BPL), was the first humanized monoclonal antibody in China since 2008, with positive achievements in the fight against nasopharyngeal cancer, Bai Xianhong, director, stressed to Prensa Latina of the entity. Yanet Borrego, deputy general director and representative of the Cuban vice presidency of BPA declared that the high rate of diseases imposes the urgency of creating new methodologies to treat them.
As part of a parallel event, the southern province of Hunan presented the Friendship Medal to Cuban specialist Yasser Perera, scientific director of the Cuba-China Biotechnology Joint Innovation Center, in Yongzhou.
Source: Granma
